CanSino Biologics Management

Management Kriterienprüfungen 4/4

CanSino Biologics CEO ist Xuefeng Yu , ernannt in Jan 2009, hat eine Amtszeit von 15.83 Jahren. Die jährliche Gesamtvergütung beträgt CN¥3.97M , bestehend aus 64.1% Gehalt und 35.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 11.96% der Aktien des Unternehmens, im Wert von HK$1.37B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.8 Jahre bzw. 3.1 Jahre.

Wichtige Informationen

Xuefeng Yu

Geschäftsführender

CN¥4.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	64.1%
Amtszeit als Geschäftsführer	15.8yrs
Eigentum des Geschäftsführers	12.0%
Durchschnittliche Amtszeit des Managements	6.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.1yrs

Jüngste Management Updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

Recent updates

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Nov 11

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Xuefeng Yu im Vergleich zu den Einnahmen von CanSino Biologics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-CN¥720m
Jun 30 2024	n/a	n/a	-CN¥867m
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥5m	CN¥2m	-CN¥909m

Vergütung im Vergleich zum Markt: XuefengDie Gesamtvergütung ($USD547.93K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD482.15K).

Entschädigung vs. Einkommen: XuefengDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Xuefeng Yu (59 yo)

15.8yrs

Amtszeit

CN¥3,965,000

Vergütung

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xuefeng Yu	Co-Founder	15.8yrs	CN¥3.97m	11.96% HK$ 1.4b
Tao Zhu	Co-Founder	15.8yrs	CN¥4.42m	7.27% HK$ 833.1m
Dongxu Qiu	Co-Founder	15.8yrs	CN¥3.74m	11.42% HK$ 1.3b
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.5yrs	CN¥3.93m	0.0081% HK$ 928.1k
Jing Wang	Chief Commercial Officer	3.2yrs	CN¥4.57m	0.0072% HK$ 826.1k
Chunlin Xin	Senior Director of New Technology Department	7yrs	keine Daten	keine Daten
Yonghui Wu	Vice President of Marketing	no data	keine Daten	keine Daten
Jin Cui	Board Secretary	5.7yrs	keine Daten	keine Daten
Ming King Chiu	Joint Company Secretary	5.7yrs	keine Daten	keine Daten

6.8yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: 6185Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xuefeng Yu	Co-Founder	15.8yrs	CN¥3.97m	11.96% HK$ 1.4b
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.4yrs	CN¥3.93m	0.0081% HK$ 928.1k
Jing Wang	Chief Commercial Officer	3.1yrs	CN¥4.57m	0.0072% HK$ 826.1k
George R. Siber	Co-Chair of Scientific Advisory Board	1.8yrs	keine Daten	keine Daten
Shan Lu	Member of the Scientific Advisory Board	2.5yrs	keine Daten	keine Daten
Shuifa Gui	Independent Non-Executive Director	5yrs	CN¥300.00k	keine Daten
Luis Barreto	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	keine Daten	keine Daten
Jianzhong Liu	Independent Non-Executive Director	5yrs	CN¥300.00k	0.00040% HK$ 45.8k
Liming Li	Co-Chair of Scientific Advisory Board	1.8yrs	keine Daten	keine Daten
Jingren Zhang	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Leung Cheung Yiu	Independent Non-Executive Director	no data	keine Daten	keine Daten

3.1yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: 6185Die Vorstandsmitglieder gelten als erfahren (3.1 Jahre durchschnittliche Amtszeit).

CanSino Biologics Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Recent updates

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

New minor risk - Profitability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?